Drug intelligence / Profile preview

tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + influenza virus vaccine, inactivated

Development stage
Unknown
Lead developer
Sanofi
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This combination refers to the concomitant administration of the Tdap vaccine (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) and the inactivated influenza vaccine (IIV). Tdap is a booster vaccine intended for adolescents and adults to maintain immunity against tetanus (caused by *Clostridium tetani*), diphtheria (caused by *Corynebacterium diphtheriae*), and pertussis (whooping cough, caused by *Bordetella pertussis*). The inactivated influenza vaccine provides seasonal protection against various strains of the influenza virus, typically including two A subtypes and two B lineages. Clinical studies have demonstrated that co-administration of these vaccines is safe, well-tolerated, and does not interfere with the immune response to any of the individual components, facilitating improved compliance with adult immunization schedules. The Tdap component typically contains toxoids and purified antigens adsorbed onto aluminum salts, while the influenza component consists of inactivated split-virion or subunit antigens.

Other names
Tdap + IIVTdap and influenza vaccine co-administrationtetanus, diphtheria, and acellular pertussis vaccine + inactivated influenza vaccine
02

Targets

BCR (Immunoglobulin G B Cell Receptor)Diphtheria toxinFHA (Filamentous hemagglutinin)FIM2/FIM3 (Bordetella pertussis fimbriae 2/3)HA (Hemagglutinin)PRN (Pertactin)γδ TCR (T-cell receptor)T1F (Type 1 fimbriae)TT (Tetanus toxoid)

Beyond the preview

Go deeper on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + influenza virus vaccine, inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + influenza virus vaccine, inactivated.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call